United Therapeutics reports Q1 EPS $5.82, consensus $6.86

Reports Q1 revenue $781.5M, consensus $797.38M. “In Q1, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies,” said CEO Martine Rothblatt. “These readouts have the potential to meaningfully expand the breadth of our future growth and support further revenue diversification while reinforcing our long-term commitment to advancing therapies for patients with serious cardiopulmonary and respiratory disease. Moreover, given these successes, we’re excited to announce our development plans in pulmonary hypertension and fibrosis for ralinepag DPI, which we believe has the potential to achieve once-daily dosing and help broaden our therapeutic reach greater than ever before.” COO Michael Benkowitz added, “While the competitive landscape for inhaled prostacyclins remains dynamic, our continued growth for Tyvaso DPI reflects the resilience of our commercial strategy. Going forward, we are committed to further sharpening our execution with relentless drive and unwavering discipline to return to sequential quarterly revenue growth across our commercial portfolio in the near term.”